


Catalysis Science & Technology

rsc.li/catalysis



ISSN 2044-4761



Cite this: *Catal. Sci. Technol.*, 2024, 14, 2390



Received 1st October 2023,
Accepted 29th February 2024

DOI: 10.1039/d3cy01370g

rsc.li/catalysis

A transaminase-mediated aldol reaction and applications in cascades to styryl pyridines†

Yu Wang, ^a Yiwen Li, ^b Yeke Ni, ^a Dejan-Krešimir Bučar, ^a Paul A. Dalby, ^b John M. Ward, ^b Jack W. E. Jeffries ^{*b} and Helen C. Hailes ^{*a}

Transaminase enzymes are well established biocatalysts that are used in chemical synthesis due to their beneficial sustainability profile, regio- and stereoselectivity and substrate specificity. Here, the use of a wild-type *Chromobacterium violaceum* transaminase (CvTAm) in enzyme cascades revealed the formation of a novel hydroxystyryl pyridine product. Subsequent studies established it was a transaminase mediated reaction where it was exhibiting apparent aldolase reactivity. This promiscuous enzyme reaction mechanism was then explored using other wild-type transaminases and *via* the formation of CvTAm mutants. Application of one pot multi-step enzyme cascades was subsequently developed to produce a range of hydroxystyryl pyridines.

Introduction


Biocatalysis has become an important aspect of modern organic synthesis, both in academia and across the chemical and pharmaceutical industries. Its success has been largely due to a rapid expansion of the range of chemical reactions accessible and substrates accepted. Applications of naturally occurring enzymes, however, can be limited by narrow substrate specificities. Some classes of enzymes do show good native enzyme substrate promiscuity where the same transformation is performed and is due to active site plasticity or alternative substrate binding modes. Recently, interest has also focused on discovering functional enzyme promiscuity where enzymes can additionally catalyse a non-physiological reaction.¹ Examples include hydrolytic enzymes such as porcine pancreatic lipase and a peptidase from *Sulfolobus tokodaii* that have been reported to catalyse aldol reactions.^{1–4} Enzyme mutagenesis has been reported to modify enzyme functionality and an early example was a single mutation in alanine racemase which converted it into an aldolase.^{5,6} More recently, a range of new to nature enzyme functionalities have been reported such as photoinduced enzyme catalysis with ene reductases and variants *via* radical mechanisms for asymmetric reduction, hydroalkylation and

conjugate addition.^{7–9} Enzyme engineering to produce other new enzyme functionalities such as efficient Morita–Baylis–Hillman and cyclopropanes have also been described, highlighting the potential of new biocatalysts for use in synthesis.^{10–12}


Transaminases (TAMs) are well established biocatalysts that reversibly transform a ketone or aldehyde group into an amine moiety using an amine donor and the co-factor pyridoxal 5'-phosphate (PLP) **1**.^{13,14} When using prochiral ketones, the products can be single enantiomers and TAMs have been used in numerous applications towards single isomer pharmaceutical ingredients, biologically active compounds, and small molecule amines not readily accessible *via* traditional synthetic routes.^{15–20}

In this study, while incorporating the transaminase from *Chromobacterium violaceum* (*CvTAm*)²¹ into biocatalytic

Previous work: Enzyme cascades to non natural alkaloids



Current work: Enzyme cascades to styryl pyridines



Scheme 1 Previous work using cascades to alkaloids and novel aldolase activity mediated by CvTAm in this work giving rise to styryl pyridines.

^a Department of Chemistry, University College London, 20 Gordon Street, London, WC1H 0AJ, UK. E-mail: h.c.hailes@ucl.ac.uk

^b Department of Biochemical Engineering, University College London, Gower Street, London, WC1E 6BT, UK. E-mail: jack.jeffries.12@ucl.ac.uk

† Electronic supplementary information (ESI) available: Experimental methods, supporting figures and tables and chemical characterization, dynamic simulations (Movies S1–S3, mpgs). CCDC 2271746 contains the supplementary crystallographic data for **3b**. For ESI and crystallographic data in CIF or other electronic format see DOI: <https://doi.org/10.1039/d3cy01370g>

to give benzylisoquinoline alkaloids (BIAs), a novel product was identified, arising from one of the aldehydes formed *in situ* from a CvTAm reaction and subsequent aldol condensation. Investigations revealed that CvTAm appeared to catalyse the aldol reaction, and this was explored further *via in silico* enzyme modelling and the production of CvTAm variants. Applications of this new CvTAm functionality were then applied in multistep one-pot enzyme cascades incorporating a tyrosinase (TYR), tyrosine decarboxylase (TyrDC) and CvTAm to generate complex styryl pyridines (Scheme 1), which are a promising class of molecules for several biological targets.

Results and discussion



Initial hydroxystyryl pyridine formation

In previous work one-pot enzyme cascades were developed to generate new BIAs, starting from L-tyrosine 2a and analogues. Several recombinant enzymes in *E. coli* were used, a tyrosinase from *Candidatus Nitrosopumilus salaria* BD31 (CnTYR), tyrosine decarboxylase from *Enterococcus faecalis* DC32 (EfTyrDC), CvTAm and *Thalictrum flavum* noroclaurine synthase (TfNCS) to produce, *in vitro*, alkaloids such as norlaudanosoline in high yields and stereoselectivities.^{22,23} In subsequent work, parallel cascades were constructed using CnTYR and variants together with a EfTyrDC to produce the arylethylamine component, and EfTyrDC and CvTAm to produce arylacetaldehydes, enabling the use of two different amino acid starting materials. Addition of TfNCS was then able to generate novel doubly halogenated

BIAs.²⁴ When generating arylacetaldehydes *in situ* from 2a and analogues, it was noted that an unknown side-product 3a was formed. While these could readily be separated from the BIA products, we were intrigued to understand how they were formed to streamline future cascade design.

NMR spectroscopic analysis confirmed that the new product 3a, formed when using 2a, was not a BIA with the characteristic tetrahydroisoquinoline signals, ruling out the involvement of TfNCS. The presence of a deshielded proton at ~8.2 ppm suggested that it could be a pyridinium species arising from 1. *Ortho*-aryl couplings indicated that hydroxylation using CnTYR had not occurred, and that intermediates present including tyramine 4a, formed by an *in situ* decarboxylation with EfTyrDC, or 4-hydroxylphenylacetaldehyde 5a generated by a subsequent reaction with CvTAm, may be involved. Accurate mass spectrometry (MS) data (*m/z* 286.1072) corresponded to the addition of 1 and 5a and loss of H₂O (and hydrolysis of the phosphate group), suggesting an aldol addition. Analysis of the NMR data indicated key NOEs between a CH₂ group and alkene CH, the latter also giving rise to an NOE with the aryl group (Scheme 2). Together, this suggested that 3a was 5-(hydroxymethyl)-3-(4-hydroxyphenyl)-8-methyl-2H-pyranopyridine, and this was consistent with results of single crystal X-ray diffraction studies of a trifluoroacetate salt of 3a-OEt – an ethoxy hemiacetal of 3a obtained through recrystallization from ethanol.

Recent studies have reported that some (*E*)-4-(substituted styryl)pyridines, structurally related to resveratrol, inhibited



Scheme 2 Formation of 3a and key characterisation data. A. COSY NMR spectra of 3a with a key long-range coupling indicated with double headed arrows and assignments using coloured circles. Also, the molecular structure of the 3a-OEt trifluoroacetate cation, as derived from single crystal X-ray diffraction analyses; B NOESY NMR spectra of 3a showing key NOEs with double headed arrows, and proton assignments.



the formation of the vascular endothelial growth factor (VEGF) from HT-29 cells and expression of the telomerase-related *hTERT* and *c-Myc* genes.²⁵ Other hydroxystyryl pyridines have been determined to act as aldose reductase inhibitors for type II diabetes applications.²⁶ The hydroxystyryl pyridine **3a** was therefore a potentially interesting pharmacophore, and also due to the unusual mode of formation the reaction was explored in more detail to give a range of styryl pyridines.


Exploring the reaction conditions required for styryl pyridine formation

To establish whether the aldol addition to produce **3a** was enzymatically catalysed or due to the presence of particular buffers, phenylacetaldehyde **5b** and **1** were initially reacted together in different buffers or water (Table 1a), including 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES) buffer (50 mM, pH 5.5 and pH 7.5), potassium

phosphate (KPi) buffer (300 mM, pH 5.5 and pH 7.5) and 2-amino-2-hydroxymethyl-propane-1,3-diol (Tris) buffer (100 mM, pH 5.5 and pH 7.5). While all reactions gave rise to three new peaks (P_1 – P_3) (P_4 is **5b**) after 16 h by HPLC analysis, they were mixtures of uncharacterized side products (potentially formed *via* the enol of **5b**) confirming that the formation of the styryl pyridine **3b** was enzyme mediated.

Enzymes used in the original enzyme cascade were then investigated including an empty cell vector lysate, lysates of *CnTYR*, *EfTyrDC*, *CvTAm* and *TfNCS*. In agreement with the preliminary observations, *CnTYR* and *TfNCS* were not involved in the styryl pyridine formation, giving rise to peaks P_1 – P_4 only, and this was also the case for *EfTyrDC*. However, the reaction with *CvTAm* gave a new product (P_5 , Table 1b) and separation by preparative HPLC followed by characterisation by NMR spectroscopy (COSY, NOESY, Fig. 1) indicated the structure as the aldol product **3b**. Single crystal X-ray diffraction analysis also confirmed the structure of **3b** (Fig. 1A).

Table 1 Exploring the reaction conditions for the aldol addition to give styryl pyridine **3b**



a							450 350 250 150 50 -50		Peak height (mAU)		4 2 0 -50					
Buffer	H ₂ O		HEPES		KPi		Tris									
	pH 5.5	pH 7.5	pH 5.5	pH 7.5	pH 5.5	pH 7.5	pH 5.5	pH 7.5								
New peaks (P_x)	1–3	1–3	1–3	1–3	1–3	1–3	1–3	1–3								

b						350 250 150 50 -50		Peak height (mAU)	4 2 0 -50	2 4 6 8 10
Enzyme	Empty lysates	<i>CnTYR</i>	<i>EfTyrDC</i>	<i>CvTAm</i>	<i>TfNCS</i>	350 250 150 50 -50		Peak height (mAU)	4 2 0 -50	2 4 6 8 10
New peaks (P_x)	1–3	1–3	1–3	1–3, 5 (3b)	1–3					

c						350 250 150 50 -50		Peak height (mAU)	4 2 0 -50	2 4 6 8 10
TAm	<i>CvTAm</i>	<i>VfTAm</i>	<i>MvTAm</i>	<i>ArRMut11</i>	<i>KpTAm</i>	350 250 150 50 -50		Peak height (mAU)	4 2 0 -50	2 4 6 8 10
New peaks (P_x)	1–3, 5 (3b)	1–3	1–3	1–3	1–3					
TAm	<i>RsTAm</i>	Metagenomic pQR2189	Metagenomic pQR2191	Metagenomic pQR2208						
New peaks (P_x)	1–3	1–3	1–3	1–3						

Reaction conditions: (a) **5b** (10 mM, 1 equiv.) and **1** (15 mM, 1.5 equiv.) was added to reaction buffers, and 10% (v/v) DMSO as a co-solvent; (b and c) 10% (v/v) enzyme lysates (4 mg mL⁻¹ total protein) were added. Reactions were performed at 37 °C for 16 h and monitored by analytical HPLC at 280 nm. Note: P_4 is **5b**.






Fig. 1 Key characterisation data for **3b**. **A**, COSY NMR spectra of **3b** with a key long-range coupling indicated with the double headed arrows and assignments using coloured circles. Also, the molecular structure of the **3b** trifluoroacetate cation, as derived from single crystal X-ray diffraction analyses; **B** NOESY NMR spectra of **3b** showing key NOEs with double headed arrows, and proton assignments.

The apparent promiscuous ability of *CvTAm* to catalyze an aldol addition of arylacetaldehydes **5a** and **5b** to **1** was intriguing and so initially studies were carried out to determine whether other transaminases could also catalyze the reaction. Using **5b** and **1** again as starting materials, the (*R*)-selective transaminase from *Mycobacterium vanbaalenii*

(*MvTAm*)²⁷ and *Arthrobacter* sp. (*ArRmut11*),¹⁵ and (*S*)-selective transaminases from *Vibrio fluvialis* (*VfTAm*),²⁸ *Klebsiella pneumoniae* (*KpTAm*; from UCL plasmid pQR1005)^{29,30} and *Rhodobacter sphaeroides* (*RsTAm*; from UCL plasmid pQR 1019)^{30,31} were selected due to their previous biocatalytic applications. Several other




Fig. 2 Molecular docking studies using *CvTAm* (dimer) with styryl pyridine **3b**. **A**. For aldolase activities, ligand **3b** (orange) was located between Lys_{288.A} and Lys_{90.B} (subunit A in blue and subunit B in pink, active sites in red square). For transaminase activities, **1** interacts with Lys₂₈₈. **B** and **C**. Transaminase active sites are located at the central of each subunit. **D**, **E** and **G**. Potential aldolase active sites located in a cleft between the dimeric subunits. **F**. Potential catalytic sites for the aldol condensation and (known) transamination are distinct. Figures were generated using UCSF ChimeraX.^{43,44}



transaminases from a drain metagenome, expressed from plasmids pQR2189, pQR2191, and pQR2208 which have shown good activity towards aromatic amines, were also selected to test in the reaction.^{32,33} CvTAm gave a reasonable yield (42%) of **3b**. Notably, none of the other transaminases gave **3b** (Table 1c). This data indicated that CvTAm was distinctive in being able to effectively catalyse the aldol addition to give styryl pyridines.

To try and establish the key residues in CvTAm that gave rise to the aldolase activity, molecular docking studies with *apo* CvTAm (PDB: 4BA4)³⁴ and **3b** were performed using AutoDock Vina.^{35,36} Analysis of the liganded structures revealed that **3b** (for five conformations out of nine with the lowest energies) was located in a cleft between the dimeric subunits of CvTAm (Fig. 2 and Table S2†). Thus, it is likely that the catalytic site for the aldol condensation is distinct from the catalytic site for transaminase activity (Fig. 2F). Type I aldolases such as 2-deoxyribose-5-phosphate aldolase (DERA), contain two key lysine residues in the catalytic site, one which forms a Schiff base intermediate, with a second residue nearby to perturb the pK_a of the reactive lysine.³⁷⁻³⁹ Inspired by this concept it was considered that key residues in CvTAm for the aldol addition could be two lysines, positioned at the cleft between the subunits with one lysine residue located on each subunit and one lysine forming an imine with one of the substrates. Modelling positioned **3b** in close proximity to Lys_{288.A} and Lys_{90.B} (the distance between Lys_{288.A} and Lys_{90.B} is 14.2 Å, and we recognise that this is a larger distance than in native and evolved aldolases,³⁷⁻³⁹ Fig. S7A†) suggesting that these may potentially be involved in the promiscuous aldolase activity. Other transaminases including *VfTAm* (PDB: 5ZTX,⁴⁰ Lys_{285.A} and Lys_{126.B}, Fig. S7B†) *ArRmut11* (PDB: 3WWJ,⁴¹ Lys_{188.A} and Lys_{142.B}, Fig. S7C†) have the equivalent residues. However, no aldol additions were

observed, possibly due to the greater separation of the two lysine residues (24.4 Å for *ArRmut11*), although for *VfTAm* the distance was similar to *CvTAm* (14.6 Å), suggesting other factors may be important. No equivalent residues were found for *KpTAm* (PDB: 3I5T,⁴² Fig. S7D†).

To establish whether these are the key catalytic residues, the CvTAm variants K288T, K90T and double mutant K90T/K288T were generated, as threonine has a smaller size compared to lysine, but retains the polar residue characteristics and is uncharged. The single mutants were generated by site directed mutagenesis and the K90T mutant was then used as a template for the creation of the double mutant. Reactions using phenylacetaldehyde **5b** and **1** were performed with purified CvTAm WT, K288T, K90T, K90T/K288T (0.1 mg mL⁻¹) and an empty vector control. WT CvTAm only gave the product **3b** (Fig. 3A). When reacting tyramine **4a** (to produce **5a** *in situ*) and **1**, the aldol product **3a** again was only formed with WT CvTAm (Fig. 3B). The experiments with K288T resulted in the loss of transamination activity with no formation of **5a** as expected, as Lys₂₈₈ is a key mechanistic lysine. In addition, while the transamination reactivity was retained in K90T giving **5a**, the aldol addition activity was lost. The double mutant K90T/K288T also lost all transaminase and aldol activities (Fig. 3). These experiments supported the hypothesis that Lys₂₈₈ and Lys₉₀ have key mechanistic roles in the aldol reaction.

A possible mechanism is shown in Scheme 3. Firstly, aldehyde **5b** could be protonated by Lys_{288.A} and nucleophilic attack by Lys_{90.B}, would give the carbinolamine. Protonation and subsequent loss of water would give the imine and subsequent deprotonation of the α -proton by Lys_{288.A}, would give the key enamine. This can then attack the carbonyl carbon in **1** with protonation from Lys_{288.A} to give the aldol product and subsequent imine hydrolysis would give the corresponding aldehyde. Intramolecular hemiacetal





Fig. 3 HPLC traces of CvTAm reactions showing key HPLC product peaks. A. HPLC traces of CvTAm reaction with **5b** and **1**; B. HPLC traces of the CvTAm reaction with **4a** and **1**. Reaction conditions: **5b** or **4a** (10 mM, 1 equiv.) and **1** (15 mM, 1.5 equiv.) were added to reaction buffers, and 10% (v/v) DMSO as a co-solvent. To initiate the reactions, 0.1 mg mL⁻¹ purified enzyme was added. Reactions were performed at 37 °C for 16 h and monitored by analytical HPLC at 280 nm.





Scheme 3 Proposed mechanism for the aldol addition by CvTAm to give (after purification) styryl pyridine **3b**. Note that the roles of Lys₂₈₈ and Lys₉₀ could be reversed.

formation followed by phosphate hydrolysis would generate **3b** (Scheme 3). It was considered that phosphate hydrolysis likely occurred during the purification step and this is discussed further in the following section. Other potential aldol mechanisms are also possible such as switching which aldehyde forms the Lys imine: first PLP imine formation and then the aldol addition of **5b**, with subsequent elimination of the Lys.

To investigate the potential competition between transamination activity and aldol activity, kinetic studies were performed. Firstly, the concentration of pyruvate was optimised. The results showed that pyruvate did not participate in the aldol addition but instead acted as an amine accepter for transamination activity. Therefore, pyruvate was used at 1 eq. to **4a** (1 eq., 10 mM, Fig. S9†). Different ratios of **1** (0–2.5 eq.) to **4a** (1 eq., 10 mM) were also tested with purified WT CvTAm (0.1 mg mL^{−1}). With lower equivalents of **1** (<0.1 eq.), only the transamination product **5a** was formed. The aldol product **3a** was observed at higher equivalents of PLP **1** (>0.2 eq.) and reached its maximum at 1.5 eq. of **1** (48% yield by HPLC analysis, Fig. S10†). Therefore, for the kinetic study of CvTAm for aldolase activity, **1** was used at 1.5 eq. to the substrate **4a** and 1 eq. pyruvate was used. The CvTAm kinetic studies were

















performed with 0.1 eq. of **1** and 1 eq. of pyruvate, revealing that the transaminase activity ($k_{\text{cat,app}}/K_{\text{m,app}} = 3.57 \text{ s}^{-1} \text{ mM}^{-1}$, $K_{\text{m,app}} = 1.69 \text{ mM}$ and $k_{\text{cat,app}} = 6.04 \text{ s}^{-1}$) is about 20 times higher than the aldolase activity ($k_{\text{cat,app}}/K_{\text{m,app}} = 0.18 \text{ s}^{-1} \text{ mM}^{-1}$, $K_{\text{m,app}} = 9.84 \text{ mM}$ and $k_{\text{cat,app}} = 1.75 \text{ s}^{-1}$). This also suggests that the aldolase activity has little effect on the transaminase reaction.

Exploring the substrate scopes for the aldol addition to give styryl pyridines by CvTAm

The substrate scope for the production of styryl pyridines using CvTAm was then investigated. Tyramine **4a** as before, dopamine **4c**, *meta*-tyramine **4d** and *ortho*-tyramine **4e** were selected, with a view to them forming the corresponding aldehydes *in situ* and reacted with **1**. Both **4a** and **4e** gave the products **3a** and **3e**, respectively (Table 2). While **4c** and **4d** can readily form the corresponding aldehydes,^{23,24} the presence of the *meta*-OH appeared to inhibit the aldol reaction. The scope of the aldehydes accepted was then investigated using 2-pyridinecarboxaldehyde **6a**, 4-pyridinecarboxaldehyde **6b**, pyrrole-2-carboxaldehyde **6c** and pyrrole-2-carboxaldehyde **6d** which were reacted with **4a** and **5b**. As shown in Table 2, the pyrrole carboxaldehydes



Table 2 Exploring the substrate scopes of CvTAm in aldol reactions to give styryl pyridines^a

X	Y	Product	Isolated yield (yield by HPLC)
			36% (44%)
		No aldol product	—
		No aldol product	—
			29% (37%)
			24% (35%)
			25% (36%)
		No aldol product	—
		No aldol product	—
			26% (39%)
			35% (46%)

^a Reaction conditions: starting materials X (10 mM, 1 equiv.) and Y (15 mM, 1.5 equiv.) were added to HEPES buffer (50 mM, pH 7.5), and 10% (v/v) DMSO was used as a co-solvent – 0.1 mmol reactions were performed. For reactions with 4a, 4c–4e, 1 mM 1 was also added for maintaining the transamination activity of CvTAm and 10 mM pyruvate. To initial reactions, 10% (v/v) CvTAm lysates (4 mg mL⁻¹) were added. Reactions were then carried out at 37 °C for 16 h and monitored by analytical HPLC at 280 nm against product standards.


















were not accepted, while reactions using pyridine carboxaldehydes **6a** and **6b** gave the (*E*)-styryl pyridines **7a–7d** in 35–46% (by analytical HPLC against product standards). It was noted that as previously reported,^{33,45} pyridine and pyrrole carboxaldehydes/ketones can be accepted by transaminases. Here, the pyridine-and pyrrole-substituted methylamine peaks had HPLC retention times that overlapped with **1** and sodium pyruvate, so competing aminations were not monitored. Benzaldehyde and analogues substituted with electron withdrawing groups, 2-, 3-, and 4-nitrobenzaldehyde, were also used with **5b**, but no aldol products were observed. These results indicated that a

pyridine structure appeared to be required in the electrophile for the aldol addition, perhaps to assist in the orientation of the substrate into a productive conformation.

The phosphate hydrolysis step was then explored as the loss of phosphate was potentially due to the acidic work-up and purification method used. For the reaction between **1** and **4e** (using the same conditions as previously), when this was quenched and purified in the absence of acid, it gave **3e**-phosphate as the isolated product in 28% yield (ESI† section S3). This indicated that the phosphate hydrolysis was due to the work-up and purification conditions used, rather than a transaminase-mediated step.

Table 3 One-pot enzyme cascades to halogenated hydroxystyryl pyridines

Amino acid	Cascade route	Product	Isolated yield ^a (yield by HPLC) ^b
			39% (48%)
			37% (51%)
			35% (42%)
			36% (48%)
			29% (41%)

^a Reaction conditions: **1** (10 mM, 1 equiv.) and substrate **2a–d** (15 mM, 1.5 equiv.) were added to HEPES buffer (50 mM, pH 7.5) – 0.1 mM reactions were performed. To initial reactions, 10% (v/v) enzyme lysates (4 mg mL⁻¹ total enzyme) of *CnTYR* (where used), *EfTyrDC* and *CvTAm* were added into one-pot. Reactions were performed at 37 °C for 16 h. ^b Reactions were monitored by analytical HPLC at 280 nm against product standards.



Enzyme cascades to halogenated hydroxystyryl pyridines

Enzyme cascades to halogenated hydroxystyryl pyridines were then developed, combining *Ef*TyrDC and *Cv*TAm and using **2a** and the halogenated tyrosines **2b–2d** as the starting materials as halogenated arylacetaldehydes are not readily available. First, the cascade to **3a** was optimised from **2a** using *Ef*TyrDC and *Cv*TAm to give the arylacetaldehyde, which directly condensed with **1** using *Cv*TAm giving **3a** in 39% isolated yield. Similarly, **8a** was formed from **2b** in 37% yield (51% HPLC yield, Table 2). As **2b** can also be hydroxylated by *Cn*TYR from previous work,^{23,24} this was also included in the cascade to the arylacetaldehyde, which with **1** gave the catechol styryl pyridine **8b** in 35% yield. Finally, application of the cascade without wild-type *Cn*TYR, which does not readily accept **2c** and **2d**, gave products **8c** and **8d** in 36% and 29% isolated yields, respectively (Table 3). The ability to start from readily available amino acids, and through one pot two-enzyme three-step, or three-enzyme four-step cascades, to produce complex hydroxylated styryl pyridines is a valuable route to such compounds in 29–39% yields (41–51% yields by HPLC).

As hydroxystyryl pyridines have an interesting pharmacophore, initial molecular dynamics modelling with **3a** was investigated with human pancreatic amylase (HPA) (ESI† section S6), which suggested that they could be a potential inhibitor and useful scaffold for use in future studies.

Conclusions

Here, a transaminase from *Chromobacterium violaceum* was identified as being able to catalyse the aldol addition between aryl acetaldehydes and pyridine carboxaldehydes, giving styryl pyridines and hydroxystyryl pyridines. This C–C bond formation is believed to be catalysed by two lysine residues Lys_{288.A} and Lys_{90.B} in the dimeric enzyme. Given the importance of hydroxystyryl pyridines as promising inhibitors for type II diabetes, enzyme cascades to various hydroxystyryl pyridines were established starting from commercially available amino acids. Above all, our data illustrates the potential of native enzymes to achieve promiscuous activities and produce novel products.

Author contributions

Y. W. and Y. N. performed chemical syntheses, chemical characterizations, and enzymatic assays. D-K. B. carried out the X-ray crystallography experiments and J. W. E. J. generated the enzyme variants. P. A. D., Y. L. and Y. W. performed the molecular dynamic simulations. The manuscript was written through contributions of all authors. The project was conceived by Y. W., J. W. E. J. and H. C. H., and was supervised by J. M. W., J. W. E. J. and H. C. H. All authors have given approval to the final version of the manuscript.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work was funded by a UCL Dean's Prize to Y. W. Funding from the Biotechnology and Biological Sciences Research Council (BBSRC) to J. W. E. J. (BB/N01877X/1) is gratefully acknowledged. We also acknowledge 700 MHz NMR equipment support by EPSRC (EP/P020410/1). We thank K. Karu (UCL Mass Spectrometry Facility) and A. E. Aliev (UCL NMR Facility) in the Department of Chemistry at UCL. Molecular graphics and analyses were performed with UCSF ChimeraX, developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco, with support from National Institutes of Health R01-GM129325 and the Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases.

Notes and references

- 1 R. D. Gupta, *Sustainable Chem. Processes*, 2016, **4**, 2.
- 2 A. Patti and C. Sanfilippo, *Int. J. Mol. Sci.*, 2022, **23**, 2675.
- 3 C. Li, X. W. Feng, N. Wang, Y. J. Zhou and X. Q. Yu, *Green Chem.*, 2008, **10**, 616–618.
- 4 R. Li, B. Perez, H. Jian, M. M. Jensen, R. Gao, M. Dong, M. Glasius and Z. Guo, *Appl. Microbiol. Biotechnol.*, 2015, **99**, 9625–9634.
- 5 F. P. Seebeck and D. Hilvert, *J. Am. Chem. Soc.*, 2003, **125**, 10158–10159.
- 6 M. D. Toscano, M. M. Müller and D. Hilvert, *Angew. Chem., Int. Ed.*, 2007, **46**, 4468–4470.
- 7 Y. Nakano, M. J. Black, A. J. Meichan, B. A. Sandoval, M. M. Chung, K. F. Biegasiewicz, T. Zhu and T. K. Hyster, *Angew. Chem., Int. Ed.*, 2020, **59**, 10484–10488.
- 8 X. Huang, B. Wang, Y. Wang, G. Jiang, J. Feng and H. Zhao, *Nature*, 2020, **584**, 69–74.
- 9 P. T. Cesana, C. G. Page, D. Harris, M. A. Emmanuel, T. K. Hyster and G. S. Schlau-Cohen, *J. Am. Chem. Soc.*, 2022, **144**, 17516–17521.
- 10 P. C. Coelho, E. M. Brustad, A. Kannan and F. H. Arnold, *Science*, 2013, **339**, 307–310.
- 11 R. Crawshaw, A. E. Crossley, L. Johannissen, A. J. Burke, S. Hay, C. Levy, D. Baker, S. L. Lovelock and A. P. Green, *Nat. Chem.*, 2022, **14**, 313–320.
- 12 D. C. Miller, S. V. Athavale and F. H. Arnold, *Nat. Synth.*, 2022, **1**, 18–23.
- 13 S. Mathew and H. Yun, *ACS Catal.*, 2012, **2**, 993–1001.
- 14 F. Guo and P. Berglund, *Green Chem.*, 2017, **19**, 333–360.
- 15 C. K. Savile, J. M. Janey, E. C. Mundorff, J. C. Moore, S. Tam, W. R. Jarvis, J. C. Colbeck, A. Krebber, F. J. Fleitz, J. Brands, P. N. Devine, G. W. Huisman and G. J. Hughes, *Science*, 2010, **329**, 305–309.
- 16 T. Sehl, H. C. Hailes, J. M. Ward, U. Menyes, M. Pohl and D. Rother, *Green Chem.*, 2014, **16**, 3341–3348.

17 C. S. Fuchs, J. E. Farnberger, G. Steinkellner, J. H. Sattler, M. Pickl, R. C. Simon, F. Zepeck, K. Gruber and W. Kroutil, *Adv. Synth. Catal.*, 2018, **360**, 768–778.

18 D. Baud, J. W. E. Jeffries, T. S. Moody, J. M. Ward and H. C. Hailes, *Green Chem.*, 2017, **19**, 1134–1143.

19 S. J. Novick, N. Dellas, R. Garcia, C. Ching, A. Bautista, D. Homan, O. Alvizo, D. Entwistle, F. Kleinbeck, T. Schlama and T. Ruch, *ACS Catal.*, 2021, **11**, 3762–3770.

20 A. Dunbabin, F. Subrizi, J. M. Ward, T. D. Sheppard and H. C. Hailes, *Green Chem.*, 2017, **19**, 397–404.

21 U. Kaulmann, K. Smithies, M. E. B. Smith, H. C. Hailes and J. M. Ward, *Enzyme Microb. Technol.*, 2007, **41**, 628–637.

22 B. R. Lichman, M. C. Gershater, E. D. Lamming, T. Pesnot, A. Sula, N. Keep, H. C. Hailes and J. M. Ward, *FEBS J.*, 2015, **282**, 1137–1151.

23 Y. Wang, N. Tappertzhofen, D. Méndez-Sánchez, M. Bawn, B. Lyu, J. M. Ward and H. C. Hailes, *Angew. Chem., Int. Ed.*, 2019, **58**, 10120–10125.

24 Y. Wang, F. Subrizi, E. M. Carter, T. D. Sheppard, J. M. Ward and H. C. Hailes, *Nat. Commun.*, 2022, **13**, 5436.

25 R. Martí-Centelles, J. Murga, E. Falomir, M. Carda and J. A. Marco, *Med. Chem. Commun.*, 2015, **6**, 1809–1815.

26 H. Chen, X. Zhang, X. Zhang, W. Liu, Y. Lei, C. Zhu and B. Ma, *Molecules*, 2020, **25**, 5135.

27 M. Höhne, S. Schätzle, H. Jochens, K. Robins and U. T. Bornscheuer, *Nat. Chem. Biol.*, 2010, **6**, 807–813.

28 J. S. Shin, H. Yun, J. W. Jang, I. Park and B. G. Kim, *Appl. Microbiol. Biotechnol.*, 2003, **61**, 463–471.

29 B. R. Lichman, E. D. Lamming, T. Pesnot, J. M. Smith, H. C. Hailes and J. M. Ward, *Green Chem.*, 2015, **17**, 852–855.

30 D. Baud, N. Tappertzhofen, T. S. Moody, J. M. Ward and H. C. Hailes, *Adv. Synth. Catal.*, 2022, **364**, 1564–1572.

31 M. F. Villegas-Torres, R. J. Martínez-Torres, A. Cázares-Körner, H. Hailes, F. Baganz and J. M. Ward, *Enzyme Microb. Technol.*, 2015, **81**, 23–30.

32 F. Subrizi, L. Benhamou, J. M. Ward, T. D. Sheppard and H. C. Hailes, *Angew. Chem., Int. Ed.*, 2019, **58**, 3854–3858.

33 L. Leipold, D. Dobrijevic, J. W. E. Jeffries, M. Bawn, T. S. Moody, J. M. Ward and H. C. Hailes, *Green Chem.*, 2018, **21**, 75–86.

34 C. Sayer, M. N. Isupov, A. Westlake and J. A. Littlechild, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2013, **69**, 564–576.

35 J. Eberhardt, D. Santos-Martins, A. F. Tillack and S. Forli, *J. Chem. Inf. Model.*, 2021, **61**, 3891–3898.

36 O. Trott and A. J. Olson, *J. Comput. Chem.*, 2010, **31**, 455–461.

37 T. D. Machajewski and C. H. Wong, *Angew. Chem., Int. Ed.*, 2000, **39**, 1352–1374.

38 H. Andreas, J. G. Luz, C. H. Wong and I. A. Wilson, *J. Mol. Biol.*, 2004, **343**, 1019–1034.

39 L. Giger, S. Caner, R. Obexer, P. Kast, D. Baker, N. Ban and D. Hilvert, *Nat. Chem. Biol.*, 2013, **9**, 494.

40 Y. C. Shin, H. Yun and H. H. Park, *Sci. Rep.*, 2018, **8**, 11454.

41 L. J. Guan, J. Ohtsuka, M. Okai, T. Miyakawa, T. Mase, Y. Zhi, F. Hou, N. Ito, A. Iwasaki, Y. Yasohara and M. A. Tanokura, *Sci. Rep.*, 2015, **5**, 10753.

42 Y. Patskovsky, R. Toro, J. Freeman, J. Do, J. M. Sauder, S. K. Burley and S. C. Almo, RCSB Protein Data Bank, <https://www.rcsb.org/structure/3I5T>, (accessed Feb 04, 2023).

43 E. F. Pettersen, T. D. Goddard, C. C. Huang, E. C. Meng, G. S. Couch, T. I. Croll, J. H. Morris and T. E. Ferrin, *Protein Sci.*, 2021, **30**, 70–82.

44 T. D. Goddard, C. C. Huang, E. C. Meng, E. F. Pettersen, G. S. Couch, J. H. Morris and T. E. Ferrin, *Protein Sci.*, 2018, **27**, 14–25.

45 C. E. Paul, M. Rodríguez-Mata, E. Bustos, I. Lavandera, V. Gotor-Fernández, V. Gotor, S. García-Cerrada, J. Mendiola, Ó. de Frutos and I. Collado, *Org. Process Res. Dev.*, 2014, **18**, 788–792.

